The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Current and Prospective Protein Biomarkers of Lung Cancer
Open accessAbstract
Lung cancer is a malignant lung tumor with various histological variants that arise from different cell types, such as bronchial epithelium, bronchioles, alveoli, or bronchial mucous glands. The clinical course and treatment efficacy of lung cancer depends on the histological variant of the tumor. Therefore, accurate identification of the histological type of cancer and respective protein biomarkers is crucial for adequate therapy. Due to the great diversity in the molecular-biological features of lung cancer histological types, detection is impossible without knowledge of the nature and origin of malignant cells, which release certain protein biomarkers into the bloodstream. To date, different panels of biomarkers are used for screening. Unfortunately, a uniform serum biomarker composition capable of distinguishing lung cancer types is yet to be discovered. As such, histological analyses of tumor biopsies and immunohistochemistry are the most frequently used methods for establishing correct diagnoses. Here, we discuss the recent advances in conventional and prospective aptamer based strategies for biomarker discovery. Aptamers like artificial antibodies can serve as molecular recognition elements for isolation detection and search of novel tumor-associated markers. Here we will describe how these small synthetic single stranded oligonucleotides can be used for lung cancer biomarker discovery and utilized for accurate diagnosis and targeted therapy. Furthermore, we describe the most frequently used in-clinic and novel lung cancer biomarkers, which suggest to have the ability of differentiating between histological types of lung cancer and defining metastasis rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639
Cited by
Nasrullah, N., Sang, J., Alam, M. S., Mateen, M., Cai, B., & Hu, H. (2019) · Sensors · doi:10.3390/s19173722 · Cited by 359
Recent advances in biosensor for detection of lung cancer biomarkers
Yang, G., Xiao, Z., Tang, C., Deng, Y., Huang, H., & He, Z. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111416 · Cited by 330
Diagnostic biosensors in medicine – A review
Metkar, S. K., & Girigoswami, K. (2019) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2018.11.029 · Cited by 304
Metadata
- Authors
- Zamay, T., Zamay, G., Kolovskaya, O., Zukov, R., Petrova, M., Gargaun, A., Berezovski, M., & Kichkailo, A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2017-11-13
- Volume
- 9
- Issue
- 11
- Pages
- 155
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2768512267
- Cited by
- 174
- References
- 3
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current and Prospective Protein Biomarkers of Lung Cancer. https://app.cochat.ai/papers/10.3390/cancers9110155
- The paper
- Zamay, T., Zamay, G., Kolovskaya, O., Zukov, R., Petrova, M., Gargaun, A., Berezovski, M., & Kichkailo, A. (2017). Current and Prospective Protein Biomarkers of Lung Cancer. Cancers. https://doi.org/10.3390/cancers9110155
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.